Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Affitech Signs License Agreement for Single-Chain Antibody Technology with Micromet
April 11th, 2007
Affitech AS, the privately held Norwegian biotechnology company focused on the discovery and development of therapeutic human monoclonal antibodies, announced that it has signed an agreement with Micromet AG, a biopharmaceutical company developing novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases for a non-exclusive worldwide sub-licenseable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies (SCA). Under the terms of the agreement, Affitech will have rights to conduct research involving SCA technology and will have sublicense rights to third parties for...
Source: Medical Patent Law Weekly (2007-04-11)
|
